Indian vaccines market could triple to $1.65bn by 2020: McKinsey
This article was originally published in Scrip
India's "small and underpenetrated" vaccines market could potentially scale the $1.60 billion mark in value in 2020, growing at 20% year-on-year this year onwards, if backed by appropriate public market interventions and initiatives by the government and the private sector, according to a report by McKinsey & Company and the Organisation of Pharmaceutical producers of India (OPPI).
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
The head of global vaccine and plasma segments, bioprocessing, at German multinational Merck discusses key aspects around evolving vaccine manufacturing to improve the efficiency and speed of response during a pandemic. Pre-existing manufacturing platforms, the executive says, could compress process development work and fast-track scale-up.
Glenmark and Sun Pharma introduce nintedanib generics in India at a fraction of the innovator product’s price, vying for a share of the IPF market where pirfenidone currently holds sway.